HLA分子:对CAR T细胞治疗的另一个挑战
Ikram Salih1, Meryem Fakhkhari2, Hicham Berrougui3
1Research Laboratory in Oral Biology and Biotechnology, Faculty of Dental Medicine, Mohammed V University in Rabat, Rabat, Morocco; Department of Medicine, Geriatric Service, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 4N4, Canada.
Current research in translational medicine
|October 14, 2025
概括
卡特-T细胞疗法对血液癌症有前途,但面临着免疫逃避等挑战. 针对人类白细胞抗原 (HLA) 分子的策略,如HLA-G和HLA-DR,是提高CAR-T细胞有效性的关键.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 化学抗原受体 (CAR) -T细胞疗法是血液恶性瘤的革命性治疗方法,提供持久的缓解.
- 关键的局限性包括抗原损失,免疫逃避和不利的瘤微环境,这些都会降低CAR-T细胞的疗效.
- 卡-T细胞与人类白细胞抗原 (HLA) 分子,特别是HLA-DR和HLA-G之间的相互作用存在重大障碍.
研究的目的:
- 调查HLA-DR和HLA-G在CAR-T细胞治疗耐药性的作用.
- 探索调节HLA表达的治疗策略,以提高CAR-T细胞的结果.
- 了解遗传HLA变异对血液恶性瘤和治疗反应的影响.
主要方法:
- 在CAR-T细胞治疗的背景下对单细胞上的HLA-DR和HLA-G表达的分析.
- 审查HLA的遗传变异及其与血液性恶性瘤的关联.
- 对针对HLA分子的潜在治疗干预措施的评估.
主要成果:
- 低或负的HLA-DR表达和单细胞上高的HLA-G存在与免疫逃避和CAR-T细胞有效性的降低有关.
- 遗传HLA变异影响了血液恶性瘤的易感性和进展.
- 向HLA-G和HLA-DR显示了克服抗性机制的潜力.
结论:
- 调节HLA表达和功能对于提高CAR-T细胞治疗成功至关重要.
- 像阻止HLA-G,促进HLA-DR,以及为HLA优化进行基因编辑等策略是有前途的.
- 对HLA介导免疫调节的进一步研究对于推进CAR-T细胞疗法至关重要.
相关概念视频
Antigens Involved in Adaptive Immunity
1.3K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
1.3K
Tissue Transplantation
907
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
907
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
T Cell Activation and Clonal Selection
14.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.7K
Antigen Processing Pathways
2.1K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
2.1K
Cell-mediated Immune Responses
83.5K
Overview
83.5K


